These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
78 related articles for article (PubMed ID: 15920126)
1. Pfizer Australia is fined for misleading promotion of celecoxib. Burton B BMJ; 2005 May; 330(7502):1230. PubMed ID: 15920126 [No Abstract] [Full Text] [Related]
2. Unconvincing Pfizer and uncertain crucifixions. Abbasi K J R Soc Med; 2006 Apr; 99(4):163. PubMed ID: 16574956 [No Abstract] [Full Text] [Related]
3. Cyclooxygenase-2 inhibitors and cardiovascular risk. Smith ER Can J Cardiol; 2005 Mar; 21(3):307-8. PubMed ID: 15776124 [No Abstract] [Full Text] [Related]
4. Raising the safety bar--the FDA's coxib meeting. Okie S N Engl J Med; 2005 Mar; 352(13):1283-5. PubMed ID: 15800221 [No Abstract] [Full Text] [Related]
5. How celecoxib could be safer, how valdecoxib might have been. Cohen JS Ann Pharmacother; 2005 Sep; 39(9):1542-5. PubMed ID: 16076909 [TBL] [Abstract][Full Text] [Related]
7. Risk of gastrointestinal effects with COX-2 inhibitors and NSAIDs: what does evidence from randomised trials show about celecoxib? Underhill JL BMJ; 2005 Dec; 331(7530):1474-5. PubMed ID: 16356996 [No Abstract] [Full Text] [Related]
8. Transparency in drug regulation: mirage or oasis? Lexchin J; Mintzes B CMAJ; 2004 Nov; 171(11):1363-5. PubMed ID: 15557590 [No Abstract] [Full Text] [Related]
9. Does celecoxib use increase the risk of cardiovascular events? Oviedo JA; Schroy PC Gastroenterology; 2005 Oct; 129(4):1348-50. PubMed ID: 16230088 [No Abstract] [Full Text] [Related]
10. Celebrex: new ad, with questionable claims. Consum Rep; 2007 Aug; 72(8):52-3. PubMed ID: 17644835 [No Abstract] [Full Text] [Related]
11. Clinical trials. Halt of Celebrex study threatens drug's future, other trials. Couzin J Science; 2004 Dec; 306(5705):2170. PubMed ID: 15618492 [No Abstract] [Full Text] [Related]
12. Cardiovascular risk associated with celecoxib. Brophy JM N Engl J Med; 2005 Jun; 352(25):2648-50; author reply 2648-50. PubMed ID: 15972876 [No Abstract] [Full Text] [Related]
13. Balancing the risks and benefits of celecoxib. Caldwell B; Beasley R; Weatherall M; Metcalfe S Am J Med; 2007 Jun; 120(6):e17. PubMed ID: 17524734 [No Abstract] [Full Text] [Related]
14. New, long-term insights from the Adenoma Prevention with Celecoxib Trial on a promising but troubled class of drugs. Dubois RN Cancer Prev Res (Phila); 2009 Apr; 2(4):285-7. PubMed ID: 19336723 [No Abstract] [Full Text] [Related]
16. [Celecoxib and the CLASS study--a statement]. Wibe E; Maehlum S Tidsskr Nor Laegeforen; 2002 Sep; 122(22):2218. PubMed ID: 12426902 [No Abstract] [Full Text] [Related]
18. Risk of gastrointestinal effects with COX-2 inhibitors and NSAIDs: study conclusions do not reflect findings for celecoxib. Feczko J BMJ; 2005 Dec; 331(7530):1473-4. PubMed ID: 16356991 [No Abstract] [Full Text] [Related]
19. Asthma attacks induced by low doses of celecoxib, aspirin, and acetaminophen. Baldassarre S; Schandene L; Choufani G; Michils A J Allergy Clin Immunol; 2006 Jan; 117(1):215-7. PubMed ID: 16387610 [No Abstract] [Full Text] [Related]
20. Cytochrome P450 2C9 genotype: impact on celecoxib safety and pharmacokinetics in a pediatric patient. Stempak D; Bukaveckas BL; Linder M; Koren G; Baruchel S Clin Pharmacol Ther; 2005 Sep; 78(3):309-10. PubMed ID: 16153401 [No Abstract] [Full Text] [Related] [Next] [New Search]